AbbVie (ABBV) Quick Ratio: History & Chart

AbbVie Inc.(ABBV)

Drug Manufacturers - General · North Chicago, IL

$263.01+1.24 (+0.47%)

Delayed quote: Sep 15, 2026, 4:00 PM EDT

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

North Chicago, IL

57,000 employees

www.abbvie.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Michael

View full financials

ABBV Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

0.69

QUICK RATIO (ACID-TEST) AVG TTM

0.63

QUICK RATIO (ACID-TEST) AVG 3Y

0.67

QUICK RATIO (ACID-TEST) AVG 5Y

0.72

QUICK RATIO (ACID-TEST) AVG 10Y

0.89

QUICK RATIO (ACID-TEST) AVG 15Y

1.14

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

+9.52%

CURRENT VS 3Y AVG

+1.56%

CURRENT VS 5Y AVG

-4.81%

CURRENT VS 10Y AVG

-22.94%

CURRENT VS 15Y AVG

-39.65%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

1.21

median of 89 covered companies

CURRENT VS SECTOR MEDIAN

-43.35%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
AbbVie Inc. (ABBV)	$464.68B	0.69	0.63	0.67	0.72
Merck & Co., Inc. (MRK)vs ›	$355.16B	1.10	1.23	1.17	1.09
Roche Holding AG (RHHBY)vs ›	$349.97B	0.95	1.16	1.07	1.01
UnitedHealth Group Incorporated (UNH)vs ›	$341.40B	0.78	0.81	0.80	0.79
Johnson & Johnson (JNJ)vs ›	$643.92B	0.81	0.81	0.84	0.91
AstraZeneca PLC (AZN)vs ›	$251.01B	0.67	0.73	0.70	0.72
Thermo Fisher Scientific Inc. (TMO)vs ›	$238.35B	1.18	1.41	1.34	1.37
Amgen Inc. (AMGN)vs ›	$202.74B	1.13	0.93	1.02	1.14
Novo Nordisk A/S (NVO)vs ›	$188.86B	0.66	0.56	0.61	0.63
Gilead Sciences, Inc. (GILD)vs ›	$181.64B	1.09	1.42	1.32	1.28

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

AbbVie Inc. (ABBV)

$464.68B

0.69

0.63

0.67

0.72

Merck & Co., Inc. (MRK)vs ›

$355.16B

1.10

1.23

1.17

1.09

Roche Holding AG (RHHBY)vs ›

$349.97B

0.95

1.16

1.07

1.01

UnitedHealth Group Incorporated (UNH)vs ›

$341.40B

0.78

0.81

0.80

0.79

Johnson & Johnson (JNJ)vs ›

$643.92B

0.81

0.84

0.91

AstraZeneca PLC (AZN)vs ›

$251.01B

0.67

0.73

0.70

0.72

Thermo Fisher Scientific Inc. (TMO)vs ›

$238.35B

1.18

1.41

1.34

1.37

Amgen Inc. (AMGN)vs ›

$202.74B

1.13

0.93

1.02

1.14

Novo Nordisk A/S (NVO)vs ›

$188.86B

0.66

0.56

0.61

0.63

Gilead Sciences, Inc. (GILD)vs ›

$181.64B

1.09

1.42

1.32

1.28

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The quick ratio (acid-test) for ABBV stock is 0.69.

Is AbbVie Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 0.69 is in line with its 5-year average of 0.72, around the middle of its 5-year range (0.54–0.91).

What is the TTM average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The TTM average quick ratio (acid-test) for ABBV stock is 0.63.

What is the 3Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 3Y average quick ratio (acid-test) for ABBV stock is 0.67.

What is the 5Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 5Y average quick ratio (acid-test) for ABBV stock is 0.72.

What is the 10Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 10Y average quick ratio (acid-test) for ABBV stock is 0.89.

What is the 15Y average quick ratio (acid-test) for AbbVie Inc. (ABBV)?

The 15Y average quick ratio (acid-test) for ABBV stock is 1.14.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	0.69
2026-03-31	0.68
2025-12-31	0.56
2025-09-30	0.60
2025-06-30	0.61
2025-03-31	0.64
2024-12-31	0.55
2024-09-30	0.54
2024-06-30	0.71
2024-03-31	0.83
2023-12-31	0.76
2023-09-30	0.84
2023-06-30	0.77
2023-03-31	0.82
2022-12-31	0.84
2022-09-30	0.83
2022-06-30	0.75
2022-03-31	0.71
2021-12-31	0.70
2021-09-30	0.91
2021-06-30	0.79
2021-03-31	0.73
2020-12-31	0.73
2020-09-30	0.81
2020-06-30	0.70
2020-03-31	3.03
2019-12-31	3.06
2019-09-30	1.04
2019-06-30	0.78
2019-03-31	0.91
2018-12-31	0.89
2018-09-30	1.08
2018-06-30	0.71
2018-03-31	1.10
2017-12-31	1.18
2017-09-30	1.32
2017-06-30	1.25
2017-03-31	1.60
2016-12-31	1.51
2016-09-30	1.61
2016-06-30	1.62
2016-03-31	1.39
2015-12-31	1.34
2015-09-30	1.82
2015-06-30	1.35
2015-03-31	1.30
2014-12-31	1.31
2014-09-30	2.49
2014-06-30	2.65
2014-03-31	2.61
2013-12-31	2.43
2013-09-30	2.24
2013-06-30	2.14
2013-03-31	2.05
2012-12-31	2.10
2012-09-30	1.86
2012-06-30	1.06
2012-03-31	1.06
2011-12-31	1.10
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

0.69

2026-03-31

0.68

2025-12-31

0.56

2025-09-30

0.60

2025-06-30

0.61

2025-03-31

0.64

2024-12-31

0.55

2024-09-30

0.54

2024-06-30

0.71

2024-03-31

0.83

2023-12-31

0.76

2023-09-30

0.84

2023-06-30

0.77

2023-03-31

0.82

2022-12-31

0.84

2022-09-30

0.83

2022-06-30

0.75

2022-03-31

0.71

2021-12-31

0.70

2021-09-30

0.91

2021-06-30

0.79

2021-03-31

0.73

2020-12-31

0.73

2020-09-30

0.81

2020-06-30

0.70

2020-03-31

3.03

2019-12-31

3.06

2019-09-30

1.04

2019-06-30

0.78

2019-03-31

0.91

2018-12-31

0.89

2018-09-30

1.08

2018-06-30

0.71

2018-03-31

1.10

2017-12-31

1.18

2017-09-30

1.32

2017-06-30

1.25

2017-03-31

1.60

2016-12-31

1.51

2016-09-30

1.61

2016-06-30

1.62

2016-03-31

1.39

2015-12-31

1.34

2015-09-30

1.82

2015-06-30

1.35

2015-03-31

1.30

2014-12-31

1.31

2014-09-30

2.49

2014-06-30

2.65

2014-03-31

2.61

2013-12-31

2.43

2013-09-30

2.24

2013-06-30

2.14

2013-03-31

2.05

2012-12-31

2.10

2012-09-30

1.86

2012-06-30

1.06

2012-03-31

1.06

2011-12-31

1.10

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

Quick Ratio (Acid-Test): 0.69

ABBV Quick Ratio

ABBV Average Quick Ratio (Acid-Test) Chart

ABBV Current vs Average Quick Ratio (Acid-Test) Chart

ABBV Quick Ratio (Acid-Test) Metrics

ABBV Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

ABBV Quick Ratio (Acid-Test) History

Related Metrics